Lista de obras -

Abnormal fibrinolysis recognized by thromboelastography in a case of severe bleeding with normal coagulation and platelet function, leads to detection of a novel SERPINF2 variant causing severe alpha-2-antiplasmin deficiency

scientific article published on 08 July 2019

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia.

artículo científico publicado en 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia.

artículo científico publicado en 2017

Comparing the burden of illness of haemophilia between resource-constrained and unconstrained countries: the São Paulo-Toronto Hemophilia Study

artículo científico publicado en 2017

Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A

artículo científico publicado en 2019

Glanzmann thrombasthenia platelets compete with transfused platelets, reducing the haemostatic impact of platelet transfusions.

artículo científico publicado en 2017

Idiopathic pulmonary arterial hypertension - a unrecognized cause of high-shear high-flow haemostatic defects (otherwise referred to as acquired von Willebrand syndrome) in children

artículo científico publicado en 2018

Immunogenicity, efficacy and safety of Nuwiq(®) (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study

artículo científico publicado en 2017

Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX.

artículo científico publicado en 2017

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.

artículo científico publicado en 2017

Long-term follow-up of neonatal intracranial haemorrhage in children with severe haemophilia

artículo científico publicado en 2020

Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia

artículo científico publicado en 2022

Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool

artículo científico publicado en 2019

Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials

artículo científico publicado en 2018

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

artículo científico publicado en 2017

Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis

artículo científico publicado en 2018

Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis

artículo científico publicado en 2020

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.

artículo científico publicado en 2018

Switching to extended half-life products in Canada - preliminary data.

artículo científico publicado en 2017

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

artículo científico publicado en 2019

Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes

artículo científico publicado en 2022

Vaccinations are not associated with inhibitor development in boys with severe haemophilia A.

artículo científico publicado en 2017

WFH Guidelines for the Management of Hemophilia, 3rd edition

artículo científico publicado en 2020

Lista de obras de

Abnormal fibrinolysis recognized by thromboelastography in a case of severe bleeding with normal coagulation and platelet function, leads to detection of a novel SERPINF2 variant causing severe alpha-2-antiplasmin deficiency

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia.

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia.

Comparing the burden of illness of haemophilia between resource-constrained and unconstrained countries: the São Paulo-Toronto Hemophilia Study

Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A

Glanzmann thrombasthenia platelets compete with transfused platelets, reducing the haemostatic impact of platelet transfusions.

Idiopathic pulmonary arterial hypertension - a unrecognized cause of high-shear high-flow haemostatic defects (otherwise referred to as acquired von Willebrand syndrome) in children

Immunogenicity, efficacy and safety of Nuwiq(®) (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study

Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX.

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.

Long-term follow-up of neonatal intracranial haemorrhage in children with severe haemophilia

Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia

Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool

Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis

Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.

Switching to extended half-life products in Canada - preliminary data.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes

Vaccinations are not associated with inhibitor development in boys with severe haemophilia A.

WFH Guidelines for the Management of Hemophilia, 3rd edition